Paper Details

  1. Home
  2. Paper Details

Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses.

Author: ChangHsiu-Mei, ChenHsiao-Ling, ChenTun-Chieh, ChengHao-Min, HaoShao-Yuan, HuangWei-Hsuan, JuanYung-Shun, LeeHsiang Ying, TeohJeremy Yuen-Chun, TsaiHsin-Yi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Abiraterone is associated with an increased risk of cardiac disorders, while enzalutamide has a higher probability of causing hypertension. Clinicians should consider these different adverse effects when choosing novel hormonal agents for patients with castration-resistant prostate cancer.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Abiraterone and enzalutamide may increase the risk of cardiovascular events in patients with castration-resistant prostate cancer (CRPC). METHODS: A comprehensive literature search was performed using a combination of keywords related to "abiraterone," "enzalutamide," "prostate cancer,"...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/s41391-020-00275-3

データ提供：米国国立医学図書館（NLM）

Abiraterone and Enzalutamide: Navigating the Cardiovascular Desert

Prostate cancer, like a stubborn desert plant, can be difficult to treat. Abiraterone and enzalutamide, two promising therapies for castration-resistant prostate cancer, have shown effectiveness in controlling the disease. However, these medications have also been associated with an increased risk of cardiovascular events. This research, like a camel caravan traversing a vast and challenging landscape, explores the specific cardiovascular side effects of abiraterone and enzalutamide. The study finds that both drugs increase the risk of cardiovascular events, but with different patterns. Abiraterone is associated with a higher risk of cardiac disorders, while enzalutamide is linked to a greater risk of hypertension. This research provides valuable insights into the cardiovascular risks associated with these therapies, allowing for more informed treatment decisions and better management of these potential side effects.

Navigating the Cardiovascular Desert: Understanding the Risks

This study highlights the importance of understanding the cardiovascular risks associated with abiraterone and enzalutamide. The findings provide valuable information for healthcare professionals to tailor treatment strategies and manage these potential side effects effectively.

A Balanced Approach: Managing Prostate Cancer and Cardiovascular Health

The treatment of prostate cancer, like a delicate balancing act, requires careful consideration of the potential benefits and risks of therapy. This research emphasizes the importance of assessing cardiovascular risk factors, monitoring patients closely for cardiovascular events, and implementing appropriate preventative measures to mitigate these risks.

Dr.Camel's Conclusion

This research guides us through the vast and often treacherous desert of cardiovascular risks associated with prostate cancer treatment. By understanding the specific cardiovascular side effects of abiraterone and enzalutamide, we can navigate this landscape with greater awareness and make more informed treatment decisions.

Date :
  1. Date Completed 2021-11-24
  2. Date Revised 2022-04-22
Further Info :

Pubmed ID

32860011

DOI: Digital Object Identifier

10.1038/s41391-020-00275-3

Related Literature

Article Analysis
・Effects of enzalutamide・Effects of abiraterone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.